Practical implication
Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.
The guidance reinforces post-marketing safety reporting obligations for ANDA holders, including consistent submission of safety data and periodic reports to FDA.
What changed: FDA published final guidance on certain postapproval requirements for ANDA holders, reiterating obligations for post-approval supplements, annual reports, and post-marketing safety reporting under 21 CFR 314.80.
Why it matters: This guidance impacts all ANDA holders by clarifying FDA expectations for safety reporting and maintenance, ensuring compliance with post-marketing pharmacovigilance requirements.
Practical implication: Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.
View original source
Published from the Firecrawl policy change extraction pipeline.
